Drug Profile
Research programme: sordarin antifungals - Astellas Pharma
Alternative Names: AS1710313; FR 290581Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Astellas Pharma
- Class Indenes
- Mechanism of Action Peptide elongation factor 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Mycoses
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Mycoses in Japan (PO)
- 28 Oct 2008 Preclinical trials in Mycoses in Japan (PO)